Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis.

Ahrweiller K, Rousseau C, Le Page E, Bajeux E, Leray E, Michel L, Edan G, Kerbrat A.

Mult Scler. 2019 May 16:1352458519848090. doi: 10.1177/1352458519848090. [Epub ahead of print]

PMID:
31094285
2.

Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS.

Lavie C, Rollot F, Durand-Dubief F, Marignier R, Ionescu I, Casey R, Moreau T, Tourniaire P, Hutchinson M, D'Hooghe MB, Laplaud DA, Clavelou P, De Sèze J, Debouverie M, Brassat D, Pelletier J, Lebrun-Frenay C, Le Page E, Castelnovo G, Berger E, Hautecoeur P, Heinzlef O, Durelli L, Clerico M, Trojano M, Patti F, Vukusic S; PRIMS and POPARTMUS investigators.

Mult Scler. 2019 Apr;25(4):591-600. doi: 10.1177/1352458518763080. Epub 2018 Mar 20.

PMID:
31081475
3.

Co-occurrence of MS and ALS: a clue in favor of common pathophysiological findings?

Guennoc AM, Pallix-Guyot M, Le Page E, Le Port D, Daryabin M, Hergesheimer R, Beltran S, Tourbah A, Edan G, Corcia P.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Nov;19(7-8):500-505. doi: 10.1080/21678421.2018.1476547. Epub 2018 Sep 3.

PMID:
30175630
4.

Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.

Balloy G, Pelletier J, Suchet L, Lebrun C, Cohen M, Vermersch P, Zephir H, Duhin E, Gout O, Deschamps R, Le Page E, Edan G, Labauge P, Carra-Dallieres C, Rumbach L, Berger E, Lejeune P, Devos P, N'Kendjuo JB, Coustans M, Auffray-Calvier E, Daumas-Duport B, Michel L, Lefrere F, Laplaud DA, Brosset C, Derkinderen P, de Seze J, Wiertlewski S; Société Francophone de la Sclérose en Plaques.

J Neurol. 2018 Oct;265(10):2251-2259. doi: 10.1007/s00415-018-8984-7. Epub 2018 Jul 27.

PMID:
30054790
5.

Focal and diffuse cervical spinal cord damage in patients with early relapsing-remitting MS: A multicentre magnetisation transfer ratio study.

Combès B, Kerbrat A, Ferré JC, Callot V, Maranzano J, Badji A, Le Page E, Labauge P, Ayrignac X, Carra Dallière C, de Champfleur NM, Pelletier J, Maarouf A, de Seze J, Collongues N, Brassat D, Durand-Dubief F, Barillot C, Bannier E, Edan G.

Mult Scler. 2019 Jul;25(8):1113-1123. doi: 10.1177/1352458518781999. Epub 2018 Jun 18.

PMID:
29909771
6.

Induction or escalation therapy for patients with multiple sclerosis?

Le Page E, Edan G.

Rev Neurol (Paris). 2018 Jun;174(6):449-457. doi: 10.1016/j.neurol.2018.04.004. Epub 2018 May 22. Review.

7.

Is the Choosing Wisely® campaign model applicable to the management of multiple sclerosis in France? A GRESEP pilot study.

Trumbic B, Zéphir H, Ouallet JC, Le Page E, Laplaud D, Bensa C, de Sèze J.

Rev Neurol (Paris). 2018 Jan - Feb;174(1-2):28-35. doi: 10.1016/j.neurol.2017.06.016. Epub 2017 Nov 8.

PMID:
29128151
8.

Cognition and quality of life in clinically isolated syndrome patients starting a disease modifying therapy in the QUALICIS study may not predict treatment response at one year.

Cohen M, Brochet B, Clavelou P, Le Page E, Vermersch P, Tourbah A, Moreau T, Joly H, Sakarovitch C, Lebrun C; Qualicis Study Group.

J Neurol Sci. 2017 Nov 15;382:73-78. doi: 10.1016/j.jns.2017.09.030. Epub 2017 Sep 22.

PMID:
29111024
9.

Oral rather than intravenous corticosteroids should be used to treat MS relapses - Yes.

Le Page E, Edan G.

Mult Scler. 2017 Jul;23(8):1056-1058. doi: 10.1177/1352458517695893. Epub 2017 Feb 1. No abstract available.

PMID:
28326884
10.

Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?

Bonenfant J, Bajeux E, Deburghgraeve V, Le Page E, Edan G, Kerbrat A.

Eur J Neurol. 2017 Feb;24(2):237-244. doi: 10.1111/ene.13181. Epub 2016 Oct 18.

PMID:
27753181
11.

[Rapid improvement in visual function after high-dose oral corticosteroids in patients with inflammatory optic neuropathy].

Poujade A, Le Page E, Baudet D, Edan G, Mortemousque B, Mouriaux F.

J Fr Ophtalmol. 2016 Oct;39(8):691-699. doi: 10.1016/j.jfo.2016.03.008. Epub 2016 Aug 24. French.

12.

Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.

Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Deburghgraeve V, Coustans M, Edan G; COPOUSEP investigators; West Network for Excellence in Neuroscience.

Lancet. 2015 Sep 5;386(9997):974-81. doi: 10.1016/S0140-6736(15)61137-0. Epub 2015 Jun 28. Erratum in: Lancet. 2016 Jan 23;387(10016):340.

13.

Targeted clinical audits immediately following the establishment of clinical practice guidelines for multiple sclerosis in 17 neurology departments: A pragmatic and collaborative study.

Lairy G, Zephir H, Ouallet JC, Le Page E, Laplaud D, Bensa C, De Seze J.

Rev Neurol (Paris). 2015 May;171(5):407-14. doi: 10.1016/j.neurol.2015.03.006. Epub 2015 Apr 23.

PMID:
25912471
14.

Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.

Le Page E, Deburghgraeve V, Lester MA, Cardiet I, Leray E, Edan G.

J Neurol. 2015;262(4):1024-34. doi: 10.1007/s00415-015-7653-3. Epub 2015 Feb 21.

PMID:
25701008
15.

Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients.

Ayrignac X, Carra-Dalliere C, Menjot de Champfleur N, Denier C, Aubourg P, Bellesme C, Castelnovo G, Pelletier J, Audoin B, Kaphan E, de Seze J, Collongues N, Blanc F, Chanson JB, Magnin E, Berger E, Vukusic S, Durand-Dubief F, Camdessanche JP, Cohen M, Lebrun-Frenay C, Brassat D, Clanet M, Vermersch P, Zephir H, Outteryck O, Wiertlewski S, Laplaud DA, Ouallet JC, Brochet B, Goizet C, Debouverie M, Pittion S, Edan G, Deburghgraeve V, Le Page E, Verny C, Amati-Bonneau P, Bonneau D, Hannequin D, Guyant-Maréchal L, Derache N, Defer GL, Moreau T, Giroud M, Guennoc AM, Clavelou P, Taithe F, Mathis S, Neau JP, Magy L, Devoize JL, Bataillard M, Masliah-Planchon J, Dorboz I, Tournier-Lasserve E, Levade T, Boespflug Tanguy O, Labauge P.

Brain. 2015 Feb;138(Pt 2):284-92. doi: 10.1093/brain/awu353. Epub 2014 Dec 19.

PMID:
25527826
16.

Multiple sclerosis and pregnancy.

Bodiguel E, Bensa C, Brassat D, Laplaud D, Le Page E, Ouallet JC, Zephir H, De Seze J; Groupe de Réflexion sur la Sclérose en Plaques.

Rev Neurol (Paris). 2014 Apr;170(4):247-65. doi: 10.1016/j.neurol.2013.09.010. Epub 2014 Mar 28.

PMID:
24684929
17.

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat D, Anne O, Wiertlewski S, Camu W, Courtois S, Ruet A, Debouverie M, Le Page E, Casez O, Heinzlef O, Stankoff B, Bourre B, Castelnovo G, Rico A, Berger E, Camdessanche JP, Defer G, Clavelou P, Al Khedr A, Zephir H, Fromont A, Papeix C, Brochet B, Pelletier J, Lebrun C; Club Francophone de la Sclérose en Plaques Investigators.

JAMA Neurol. 2014 Apr;71(4):436-41. doi: 10.1001/jamaneurol.2013.6240.

PMID:
24566807
18.

Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease.

Zéphir H, Gower-Rousseau C, Salleron J, Simon O, Debouverie M, Le Page E, Bouhnik Y, Lebrun-Frenay C, Papeix C, Vigneron B, Allez M, Prin L, Cosnes J, Vermersch P, Colombel JF; CFSEP, GETAID and EPIMAD Groups.

Mult Scler. 2014 Jul;20(8):1135-9. doi: 10.1177/1352458513515081. Epub 2013 Dec 10.

PMID:
24326672
19.

Induction therapy for patients with multiple sclerosis: why? When? How?

Edan G, Le Page E.

CNS Drugs. 2013 Jun;27(6):403-9. doi: 10.1007/s40263-013-0065-y.

20.

'Clinically definite benign multiple sclerosis', an unwarranted conceptual hodgepodge: evidence from a 30-year observational study.

Leray E, Coustans M, Le Page E, Yaouanq J, Oger J, Edan G.

Mult Scler. 2013 Apr;19(4):458-65. doi: 10.1177/1352458512456613. Epub 2012 Aug 2.

PMID:
22859724
21.

Impact of pregnancy on conversion to clinically isolated syndrome in a radiologically isolated syndrome cohort.

Lebrun C, Le Page E, Kantarci O, Siva A, Pelletier D, Okuda DT; Club Francophone de Sclerose en Plaques (CFSEP); Radiologically Isolated Syndrome Consortium (RISC) Group.

Mult Scler. 2012 Sep;18(9):1297-302. Epub 2012 Feb 2.

PMID:
22300971
22.

Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients.

Kerbrat A, Le Page E, Leray E, Anani T, Coustans M, Desormeaux C, Guiziou C, Kassiotis P, Lallement F, Laplaud D, Diraison P, Rouhart F, Sartori E, Wardi R, Wiertlewski S, Edan G.

J Neurol Sci. 2011 Sep 15;308(1-2):98-102. doi: 10.1016/j.jns.2011.05.043. Epub 2011 Jun 12.

PMID:
21665227
23.

Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.

Edan G, Comi G, Le Page E, Leray E, Rocca MA, Filippi M; French–Italian Mitoxantrone Interferon-beta-1b Trial Group.

J Neurol Neurosurg Psychiatry. 2011 Dec;82(12):1344-50. doi: 10.1136/jnnp.2010.229724. Epub 2011 Mar 24.

PMID:
21436229
24.

Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.

Le Page E, Leray E, Edan G; French Mitoxantrone Safety Group.

Mult Scler. 2011 Jul;17(7):867-75. doi: 10.1177/1352458511398371. Epub 2011 Feb 15.

PMID:
21325016
25.

Evidence for a two-stage disability progression in multiple sclerosis.

Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, Edan G.

Brain. 2010 Jul;133(Pt 7):1900-13. doi: 10.1093/brain/awq076. Epub 2010 Apr 27.

26.

Neuromyelitis optica in France: a multicenter study of 125 patients.

Collongues N, Marignier R, Zéphir H, Papeix C, Blanc F, Ritleng C, Tchikviladzé M, Outteryck O, Vukusic S, Fleury M, Fontaine B, Brassat D, Clanet M, Milh M, Pelletier J, Audoin B, Ruet A, Lebrun-Frenay C, Thouvenot E, Camu W, Debouverie M, Créange A, Moreau T, Labauge P, Castelnovo G, Edan G, Le Page E, Defer G, Barroso B, Heinzlef O, Gout O, Rodriguez D, Wiertlewski S, Laplaud D, Borgel F, Tourniaire P, Grimaud J, Brochet B, Vermersch P, Confavreux C, de Seze J.

Neurology. 2010 Mar 2;74(9):736-42. doi: 10.1212/WNL.0b013e3181d31e35.

PMID:
20194912
27.

Long-term experience with induction treatment regimens in multiple sclerosis.

Le Page E, Edan G.

J Neurol Sci. 2009 Feb 1;277 Suppl 1:S46-9. doi: 10.1016/S0022-510X(09)70013-9. Review.

PMID:
19200867
28.

[Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year].

Ory S, Debouverie M, Le Page E, Pelletier J, Malikova I, Gout O, Roullet E, Vermersch P, Edan G.

Rev Neurol (Paris). 2008 Dec;164(12):1028-34. doi: 10.1016/j.neurol.2008.04.008. Epub 2008 Jun 9. French.

PMID:
18808781
29.

Acute fulminant demyelinating disease: a descriptive study of 60 patients.

de Seze J, Debouverie M, Zephir H, Lebrun C, Blanc F, Bourg V, Wiertlewski S, Pittion S, Laplaud D, Le Page E, Deschamps R, Cabre P, Pelletier J, Malikova I, Clavelou P, Jaillon V, Defer G, Labauge P, Gout O, Boulay C, Edan G, Vermersch P.

Arch Neurol. 2007 Oct;64(10):1426-32.

PMID:
17923626
30.

Long-term survival of patients with multiple sclerosis in West France.

Leray E, Morrissey S, Yaouanq J, Coustans M, Le Page E, Chaperon J, Edan G.

Mult Scler. 2007 Aug;13(7):865-74.

PMID:
17881399
31.

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

Le Page E, Leray E, Taurin G, Coustans M, Chaperon J, Morrissey SP, Edan G.

J Neurol Neurosurg Psychiatry. 2008 Jan;79(1):52-6. Epub 2007 Sep 10.

PMID:
17846110
32.

Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay.

Massart C, Gibassier J, Oger J, Le Page E, Edan G.

Clin Chim Acta. 2007 Feb;377(1-2):185-91. Epub 2006 Sep 30. Erratum in: Clin Chim Acta. 2007 May 1;380(1-2):255.

PMID:
17123498
33.

[Drug therapy in multiple sclerosis].

Le Page E, Edan G.

Rev Prat. 2006 Jun 30;56(12):1336-46. Review. French.

PMID:
16948222
34.

[Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients].

Le Page E, Leray E, Taurin G, Coustans M, Chaperon J, Edan G.

Rev Neurol (Paris). 2006 Feb;162(2):185-94. French.

PMID:
16518258
35.

Mitoxantrone in the treatment of multiple sclerosis.

Morrissey SP, Le Page E, Edan G.

Int MS J. 2005 Nov;12(3):74-87. Review.

PMID:
16417821
36.

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, Seaman S, Miller DH, Hale G, Waldmann H, Compston DA.

J Neurol. 2006 Jan;253(1):98-108. Epub 2005 Jul 27.

PMID:
16044212
37.

Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.

Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C, Coustans M, le Page E, Edan G, McDonnell GV, Hawkins S, Trojano M, Liguori M, Cocco E, Marrosu MG, Tesser F, Leone MA, Weber A, Zipp F, Miterski B, Epplen JT, Oturai A, Sørensen PS, Celius EG, Lara NT, Montalban X, Villoslada P, Silva AM, Marta M, Leite I, Dubois B, Rubio J, Butzkueven H, Kilpatrick T, Mycko MP, Selmaj KW, Rio ME, Sá M, Salemi G, Savettieri G, Hillert J, Compston DA.

Neurology. 2005 Apr 12;64(7):1144-51.

PMID:
15824338
38.

Rationale for the use of mitoxantrone in multiple sclerosis.

Edan G, Morrissey S, Le Page E.

J Neurol Sci. 2004 Aug 15;223(1):35-9. Review.

PMID:
15261558
39.

HLA-G expression in Guillain-Barré syndrome is associated with primary infection with cytomegalovirus.

Pangault C, Le Tulzo Y, Minjolle S, Le Page E, Sebti Y, Guilloux V, Fauchet R, Amiot L.

Viral Immunol. 2004;17(1):123-5. No abstract available.

PMID:
15018669
40.

[Sinus cavernous syndrome caused by isolated aspergillosis of the sphenoid sinus].

Haegelen C, Godey B, Riffaud L, Le Gall F, Le Page E, Morandi X.

Rev Neurol (Paris). 2003 Feb;159(2):209-11. French.

PMID:
12660576
41.

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis.

Ghalie RG, Mauch E, Edan G, Hartung HP, Gonsette RE, Eisenmann S, Le Page E, Butine MD, De Goodkin DE.

Mult Scler. 2002 Oct;8(5):441-5. Review.

PMID:
12356214
42.

Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS.

Brassat D, Recher C, Waubant E, Le Page E, Rigal-Huguet F, Laurent G, Edan G, Clanet M.

Neurology. 2002 Sep 24;59(6):954-5.

PMID:
12297591
43.
44.

An online sampled-data waveform control system.

Le Page EL, Johnstone BM.

Med Biol Eng. 1975 Sep;13(5):637-43. No abstract available.

PMID:
1186323

Supplemental Content

Loading ...
Support Center